Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

May 14, 2024

By Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP
Kate Cabral, PharmD, BCCP, FACC, FCCP

Opinion

Video

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

Now Viewing

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists